Updates are available Correction dated 2022-07-29
Click to view Correction: https://doi.org/10.1007/s12035-022-02975-4
-
Authors
Mondal, Koushik
Porter, Hunter
Cole, Jerome II
Pandya, Hemang K.
Basu, Sandip K.
Khanam, Sufiya
Chiu, Chi-Yang
Shah, Vinay
Stephenson, Daniel J.
Chalfant, Charles E.
Mandal, Nawajes https://orcid.org/0000-0003-4489-7748
-
Funding
Funding for this research was provided by:
National Institutes of Health (EY031316, EY022071, AI139072, GM137578, GM137394)
U.S. Department of Veterans Affairs (I01BX004893, IBX001792, IK6BX004603)
Congressionally Directed Medical Research Programs (W81XWH-20-1-0900)
- License Information
-
More Information
Article History
Received: 11 January 2022
Accepted: 1 April 2022
First Online: 15 April 2022
Change Date: 29 July 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12035-022-02975-4
Declarations
:
: Human study was approved by University of Oklahoma Institutional Review Board for the Protection of Human Subjects; IRB#: 5218; Approval Date: 02/27/2015Study Title: Sphingolipids, Autoimmune Diseases and Retinopathies.
: Human study and consent to publish was approved by University of Oklahoma; Institutional Review Board for the Protection of Human Subjects; IRB#: 5218; Approval Date: 02/27/2015.
: All the authors have seen the manuscript and approved for publication.
: Human study was approved by University of Oklahoma; Institutional Review Board for the Protection of Human Subjects; IRB#: 5218; Approval Date: 02/27/2015; Study Title: Sphingolipids, Autoimmune Diseases and Retinopathies.<b>Animals:</b> Animal studies approved by UTHSC IACUC committee. Approval # 19–0104.
: Obtained for all participants according to the approved IRB#: 5218; protocol at the University of Oklahoma. Approval Date: 02/27/2015.Study Title: Sphingolipids, Autoimmune Diseases and Retinopathies.
: None.
